Ulipristal - Boryung Pharmaceutical

Drug Profile

Ulipristal - Boryung Pharmaceutical

Alternative Names: BR-UPS

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boryung Pharmaceutical
  • Class Norpregnadienes; Oral contraceptives; Small molecules
  • Mechanism of Action Selective progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Uterine leiomyoma

Most Recent Events

  • 09 Aug 2017 Boryung Pharmaceutical withdraws a phase I trial prior to enrolment due to problem of investigational products in healthy volunteers in South Korea (PO) (NCT03156127)
  • 25 May 2017 Boryung Pharmaceutical plans a phase I trial in healthy volunteers in South Korea (NCT03156127)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top